OR WAIT null SECS
March 02, 2022
Capacity concerns and regulatory compliance considerations will drive the decision about outsourcing the manufacture of clinical trial materials.
February 21, 2022
Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.
February 17, 2022
Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.
ImmunoGen and Eli Lilly and Company have entered into an agreement that gives Lilly exclusive rights to research, develop, and commercialize ADCs designed for targets selected by Lilly from ImmunoGen’s camptothecin technology.
February 11, 2022
Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.
February 01, 2022
Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.
Recipharm will build up its biologics service offering with the acquisition of GenIbet.
January 11, 2022
The agreeement will add to Merck KGaA’s LNP and mRNA capabilities.
January 03, 2022
Workforce training is crucial for biopharmaceutical manufacturing.
December 23, 2021
Sanofi’s acquisition of Amunix will grant access to their promising immuno-oncology pipeline.